secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2026-06-04T20:29:44+00:00
Accession:  0001193125-26-257501
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta shareholders approve 2026 equity plans; elect directors at annual meeting
--------------------------------------------------------------------------------

- 2026 Equity Incentive Plan approved: 63.2M for, 4.4M against; 6,286,841 shares reserved.
- 2026 Employee Stock Purchase Plan approved: 67.1M for, 0.5M against; 1.5M shares reserved.
- Five Class I directors elected: Ingram, Wigzell, Boor, Chambers, Connelly. Connelly had 14.2M against.
- Advisory vote on named executive officer compensation passed: 45.2M for, 22.4M against.
- Ratification of KPMG as independent auditor approved: 79.9M for, 2.1M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/d88936d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer